Physician profile
James Blackburn
NPI 1952306284
$840.74
in general payments reported to CMS, 2019-2025
13 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.97 · 2021: $32.80 · 2022: $238 · 2023: $94.31 · 2024: $218 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $514.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mentor Worldwide LLC | $167.22 | 2022-2025 | Mentor Cpx 2 Breast Tissue Expander, Mentor Memoryshape Breast Implant |
| Sientra, INC. | $118.92 | 2019-2022 | |
| Allergan, INC. | $118.66 | 2019-2022 | |
| Motiva USA, LLC | $97.56 | 2024-2025 | |
| Invictus Surgical Incorporated | $69.24 | 2024 | |
| Solventum Corporation | $57.86 | 2025 | Activ.A.C., Promogran Prisma, V.A.C.Ulta |
| Tela Bio, INC. | $53.38 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Integra Lifesciences Corporation | $33.72 | 2023-2024 | Integra, Durasorb Monofilament Mesh, Surgimend |
| Mimedx Group, INC. | $31.58 | 2025 | |
| Abbvie INC. | $30.42 | 2023-2025 | Natrelle Saline-Filled Breast Implants |
| Kowa Pharmaceuticals America, INC. | $23.53 | 2023 | Seglentis |
| Axogen | $22.31 | 2022 | |
| Heron Therapeutics, INC. | $16.34 | 2024 | Zynrelef |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Blackburn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.